Amgen Loses BPCIA Suit Against Apotex’s Neulasta® and Neupogen® Biosimilars
By EsqSocial Corporation 08/09/16
Amgen’s claims against Apotex’s Neulasta® (pegfilgrastim) and Neupogen® (filgrastim) biosimilars have failed at the district court level. On September 6, 2016, the District Court for the Southern District of Florida found no infringement by Apotex...
By: Fish & Richardson